Hardman Research: Further de-risking of iclaprim

Hardman Research: Further de-risking of iclaprim

Further de-risking of iclaprim: Motif is a clinical stage development company focused on a best-in-class drug that targets bacteria resistant to most other commonly used antibiotics. The FDA has agreed a plan of two carefully constructed Phase III trials that will allow approval of iclaprim, opening it up to a $3.0bn market segment. The company has just achieved an important milestone with the last patient completing treatment in the REVIVE-1 trial, which keeps in on its revised (earlier) schedule to release headline data in 2Q 2017. Following a recent NASDAQ IPO and EU Placing, the company has sufficient capital to complete the first trial (REVIVE-1).

Please click here for the full report:

http://hardmanandco.com/docs/default-source/company-docs/motif-bio-documents/31.01.17-further-de-risking-of-iclaprim.pdf

www.hardmanandco.com

About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.